Lantus Missed-Dose Protocol: What to Do If You Skip Insulin Glargine

How Insulin Glargine Works (And Why the Timing Matters)

Insulin glargine is a long-acting basal insulin designed to provide a steady, peakless background insulin level over approximately 24 hours. Understanding the mechanism makes the missed-dose decision far less confusing.

When you inject Lantus subcutaneously, the slightly acidic formulation (pH 4.0) forms microprecipitates in the neutral pH of your subcutaneous tissue. These microprecipitates dissolve slowly and continuously, releasing insulin glargine monomers into the bloodstream at a relatively constant rate. The result is a flat, reproducible action profile with no pronounced peak, which is what separates basal insulins from mealtime (bolus) insulins.

Because there is no pronounced peak, a missed dose does not immediately cause a blood glucose spike the way a missed mealtime insulin would. Your liver keeps producing glucose overnight and between meals, though, and without basal insulin covering that hepatic glucose output, blood glucose rises steadily over hours, not minutes. That gradual drift is why the missed-dose window is forgiving, but not unlimited.

The 24-Hour Coverage Window

The prescribing information for Lantus states a duration of action of up to 24 hours, though individual variation exists. Some women find their coverage stretches closer to 20 hours; others notice fasting glucose creeping up at 18 hours if their dose is even slightly late. Pharmacokinetic studies show that the absorption plateau can vary by as much as 25 percent between individuals, and body composition, injection site, and subcutaneous fat distribution all contribute to that variability.

Glargine vs. Ultra-Long-Acting Alternatives

If you have been switched to Toujeo (insulin glargine 300 U/mL) or Tresiba (insulin degludec), the missed-dose rules are slightly different because Toujeo has a duration of up to 36 hours and Tresiba up to 42 hours. This article focuses on standard-concentration Lantus (100 U/mL). Confirm with your prescriber which formulation you are taking before applying any protocol.

The Step-by-Step Missed-Dose Protocol

Most clinical guidelines and the Lantus prescribing label share the same core framework. Here is how to apply it in practice.

Step 1. Check Your Blood Glucose First

Before injecting anything, measure your blood glucose. The result changes what you do next.

• Blood glucose <70 mg/dL (hypoglycemia): Do not inject insulin. Treat the low first with 15 grams of fast-acting carbohydrate, recheck in 15 minutes, and call your care team before proceeding.
• Blood glucose 70 to 180 mg/dL: Proceed with your usual dose.
• Blood glucose 181 to 250 mg/dL: Proceed with your usual dose and recheck in two to four hours.
• Blood glucose >250 mg/dL: Inject your usual dose and contact your prescriber or diabetes care team the same day. Check for ketones if you have type 1 diabetes. Blood glucose above 250 mg/dL alongside nausea, vomiting, or abdominal pain warrants emergency evaluation.

Step 2. Apply the Time-Since-Miss Rule

The American Diabetes Association Standards of Care do not specify an exact cutoff for basal insulin, so clinical practice draws on pharmacokinetic reasoning and endocrinology consensus.

A practical rule used widely in clinical practice:

| Hours since missed dose | Action | |---|---| | Less than 12 hours late | Inject usual dose now; resume normal schedule tomorrow | | 12 to 18 hours late | Inject usual dose now; shift tomorrow's injection back by the hours you injected late, or return to normal time if your care team approves | | More than 18 hours late (near next dose time) | Skip the missed dose entirely; inject the next scheduled dose at the normal time |

Never inject two doses within a 12-hour window under any circumstance. The basal insulin depot from partial prior absorption is still active, and a second full dose stacked on top creates a serious hypoglycemia risk.

Step 3. Document and Report Patterns

A single missed dose is a human error. Two or more missed doses in a week signals a system problem, whether that is a supply issue, an injection site problem, or a schedule that does not fit your life. Track missed doses in your glucose log and bring that log to your next telehealth visit. Persistent fasting hyperglycemia after missed doses may prompt a dose adjustment or a switch to a formulation with a longer action duration.

How Your Hormonal Status Changes the Stakes

This is where most articles on insulin glargine fall short: they ignore that the same missed dose can carry very different consequences depending on your hormonal environment. Women are not a monolith, and insulin physiology shifts substantially across the life cycle.

Reproductive Years and the Menstrual Cycle

Progesterone is insulin-antagonizing. In the luteal phase (days 15 to 28 of a typical cycle), rising progesterone increases insulin resistance, meaning your basal insulin requirement may be 10 to 20 percent higher than in the follicular phase. Research published in Diabetes Care documented measurable changes in insulin sensitivity across the menstrual cycle in women with type 1 diabetes, with glucose control consistently worsening in the luteal phase.

A practical implication: missing your Lantus dose in the follicular phase may produce only modest fasting hyperglycemia, while the identical miss in the luteal phase could push fasting glucose significantly higher because your underlying insulin resistance is already elevated. If you track your cycle alongside your glucose readings, you will often see this pattern before your prescriber mentions it.

PCOS and Insulin Resistance

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting an estimated 8 to 13 percent of women globally. Insulin resistance is a core feature of PCOS even in lean women, and up to 70 percent of women with PCOS have some degree of hyperinsulinemia.

If you have PCOS and type 2 diabetes requiring insulin glargine, your basal insulin requirement is often higher per kilogram of body weight than in women without PCOS at a similar body mass index (BMI). A missed dose in the context of elevated baseline insulin resistance means the overnight glucose drift can be steeper and faster. Checking fasting glucose every morning and keeping a tight log is especially valuable.

Perimenopause

The menopause transition is one of the most underappreciated inflection points in women's metabolic health. Estrogen has direct effects on pancreatic beta-cell function and on peripheral insulin sensitivity. As estrogen fluctuates and then declines across perimenopause (typically the mid-40s to early 50s), women who previously had stable glycemic control often find that their basal insulin requirements become unpredictable.

A 2021 review in Menopause noted that the perimenopausal period is associated with worsening insulin resistance and increased central adiposity, both of which can raise basal insulin requirements substantially. Hot flashes and disrupted sleep, which are nearly universal in perimenopause, independently worsen glucose control. If you are in perimenopause and your previously stable Lantus dose is no longer keeping your fasting glucose in range, that is a physiology problem, not a compliance problem. Ask your prescriber specifically about a perimenopause-related dose review.

Postmenopause

After the final menstrual period, estrogen stabilizes at a new low level and some of the cycle-driven insulin fluctuation resolves. Postmenopausal women on hormone therapy (HT) may find that estrogen-containing HT modestly improves insulin sensitivity, though the effect size depends on the route and type of estrogen. The WHI observational data showed lower rates of type 2 diabetes incidence in women using HT versus placebo, suggesting an insulin-sensitizing effect. That does not mean HT replaces basal insulin, but it is a reason to reassess your Lantus dose when you start, stop, or change HT.

Pregnancy and Lactation: What You Need to Know

Pregnancy changes everything about basal insulin management. This section is mandatory reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy Safety

Insulin glargine does not cross the placenta in clinically meaningful amounts based on available human data. A 2012 meta-analysis in Diabetes Care pooled data from studies comparing insulin glargine to NPH insulin in pregnancy and found no significant difference in maternal or neonatal outcomes, including neonatal hypoglycemia, large-for-gestational-age infants, or congenital anomalies.

Under the older FDA pregnancy category system, insulin glargine was classified as Category B, meaning animal studies showed no fetal harm and human data did not demonstrate a clear risk. The ACOG Practice Bulletin on Pregestational Diabetes (No. 201) acknowledges insulin glargine as a reasonable option in pregnancy when NPH is not tolerated or does not provide adequate basal coverage, though NPH remains the more extensively studied choice.

During pregnancy, insulin requirements increase substantially across trimesters:

• First trimester: Often decreased insulin sensitivity initially, then increasing demand
• Second trimester: Insulin resistance begins rising sharply after week 16 to 20
• Third trimester: Basal requirements may be 2 to 3 times pre-pregnancy levels by 36 weeks

A missed Lantus dose in the third trimester carries more consequence than at other times because the degree of insulin resistance means the glucose drift from even a few hours of missed basal coverage can be pronounced. If you are pregnant and miss a dose, call your obstetric or maternal-fetal medicine team the same day, not the next available appointment.

Gestational Diabetes

Insulin glargine is used off-label in gestational diabetes (GDM) when metformin or glyburide are insufficient or not preferred. A 2015 randomized trial in Diabetes Care compared insulin glargine to NPH in GDM and found comparable efficacy and neonatal outcomes. The missed-dose protocol for GDM is the same as above, but the glucose thresholds that prompt a call to your care team are tighter: fasting glucose above 95 mg/dL or postprandial glucose above 120 mg/dL at two hours should prompt same-day contact.

Lactation

Insulin is a large protein molecule and does not transfer into breast milk in biologically active amounts. The LactMed database (NIH) lists insulin as compatible with breastfeeding. Breastfeeding itself increases glucose utilization and can lower blood glucose, meaning postpartum women on insulin glargine may need a lower dose than during late pregnancy. Missing a dose while breastfeeding carries the additional consideration of unpredictable glucose shifts driven by feeding patterns. Check glucose before and one to two hours after feeding sessions if you are adjusting your postpartum Lantus dose.

Contraception

Insulin glargine is not a teratogen and does not require contraception as a condition of prescribing. However, women of reproductive age with poorly controlled diabetes face significantly higher risks of neural tube defects, congenital heart disease, and spontaneous abortion if they conceive during a period of hyperglycemia. The recommendation is to achieve a hemoglobin A1c below 6.5 percent (or as low as safely achievable) before attempting conception. If you are not ready to conceive, reliable contraception protects against an unplanned pregnancy during a period when glycemic control may be suboptimal.

The ORIGIN Trial: What the Evidence Actually Shows

The ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention, NEJM 2012) enrolled 12,537 people with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) and randomized them to insulin glargine titrated to a fasting glucose of 95 mg/dL or to standard care. Median follow-up was 6.2 years.

Key findings:

• Insulin glargine did not increase or decrease cardiovascular events compared to standard care (hazard ratio 1.02, 95% CI 0.94 to 1.11)
• Rates of severe hypoglycemia were low but higher in the glargine group (1.00 vs 0.31 events per 100 person-years)
• There was no signal of increased cancer incidence, which had been a theoretical concern with insulin glargine due to its higher IGF-1 receptor affinity compared to human insulin

ORIGIN enrolled approximately 35 percent women, a proportion that underrepresents the real-world female-dominant type 2 diabetes population. Sex-stratified cardiovascular outcomes were not the primary focus of the published analysis. This is a genuine evidence gap: we extrapolate the cardiovascular neutrality finding to women rather than drawing it from a predominantly female dataset. That extrapolation is reasonable but should be named.

Who Is Right for Lantus (and Who Should Discuss Alternatives)

Your prescriber makes the final call, but understanding the patient profile helps you have a more productive conversation.

Life Stages and Conditions Where Lantus Is Commonly Used

• Type 1 diabetes at any age: Basal insulin is non-negotiable. Lantus is a standard option alongside Tresiba and Toujeo.
• Type 2 diabetes, reproductive years: Lantus is effective. If you also have PCOS, discuss whether metformin or a GLP-1 receptor agonist can reduce your total insulin requirements.
• Pregnancy with type 1 or type 2 diabetes: Lantus is a reasonable option; discuss NPH versus glargine specifically with your OB or maternal-fetal medicine specialist.
• Gestational diabetes refractory to oral agents: Lantus is used off-label with reasonable safety data.
• Perimenopause or postmenopause with type 2 diabetes: Lantus remains appropriate; expect dose requirements to shift and schedule a dedicated review at the onset of the menopause transition.

Situations That Warrant a Conversation About Alternatives

• Frequent unexplained nocturnal hypoglycemia: Consider Toujeo (glargine 300 U/mL) or Tresiba (degludec), both of which have flatter profiles and fewer hypoglycemia episodes in comparative trials.
• Consistent injection site lipohypertrophy: A site rotation protocol is the first fix, but persistent lipohypertrophy unpredictably alters absorption.
• BMI <18.5 or very low subcutaneous fat: Absorption from subcutaneous sites may be erratic; discuss with your prescriber.
• Recurrent missed doses due to once-daily injection not fitting your schedule: A longer-acting option or an insulin pump may reduce the clinical consequences of schedule variability.

Practical Injection Tips That Reduce Missed Doses

Missing a dose is often a logistics failure, not a motivation failure. These strategies reduce the chances of a miss:

Set a phone alarm with a label. Use a label like "Lantus 10pm" so the alarm context is immediately clear. A generic alarm is easier to dismiss.

Pair the injection with an existing nightly habit. Tooth brushing, face washing, and setting a sleep alarm are all reliable anchors.

Keep Lantus in-use pens at room temperature. Unopened pens live in the refrigerator, but a pen in current use can be kept at room temperature (below 86 degrees Fahrenheit / 30 degrees Celsius) for up to 28 days. If the pen is cold and in the back of the refrigerator, you are more likely to skip.

Pre-fill a weekly pill organizer with pen needles. Seeing an unused needle at bedtime is a visual cue that you have not yet injected.

If you travel across time zones, discuss with your prescriber before you leave. Crossing more than three time zones warrants a specific plan. Generally, for eastward travel (shorter day), you may need to reduce the dose slightly on travel day; for westward travel (longer day), you may need to split or slightly increase. There is no single rule: individualize.

Recognizing Hyperglycemia After a Missed Dose

Knowing what missed-dose hyperglycemia feels like helps you respond faster.

Symptoms of moderate hyperglycemia (blood glucose roughly 200 to 350 mg/dL) include:

• Increased thirst and dry mouth
• Frequent urination
• Blurred vision
• Fatigue or heaviness, especially in the morning

In women specifically, prolonged hyperglycemia increases susceptibility to vaginal yeast infections and urinary tract infections (UTIs) because glucose in urine provides a growth substrate for Candida and gram-negative bacteria. A 2019 analysis in Diabetic Medicine found that women with diabetes had a two- to three-fold higher risk of recurrent vulvovaginal candidiasis compared to women without diabetes, with hyperglycemia as the primary driver. If you notice recurring yeast infections or UTIs, that is a signal to look at your overall glycemic control, including whether missed doses are contributing.

Signs of diabetic ketoacidosis (DKA), more likely in type 1 diabetes after one or more missed doses:

• Nausea or vomiting
• Abdominal pain
• Fruity-smelling breath
• Rapid breathing
• Confusion

DKA is a medical emergency. Call 911 or go to the nearest emergency department. Do not attempt to correct DKA at home.

A Note on Evidence Gaps in Women

Women have been historically underenrolled in diabetes drug trials. ORIGIN enrolled about 35 percent women. Most pharmacokinetic studies of insulin glargine were conducted predominantly in men, and the subcutaneous absorption data that underlies the 24-hour action profile comes largely from mixed-sex or male-majority cohorts. Body composition differences, specifically lower average lean mass and higher average subcutaneous fat percentage in women, could alter absorption kinetics in ways that have not been systematically studied.

The honest answer is that the clinical protocols in this article are based on physiology that is partially extrapolated from male-majority data, adjusted by clinical experience in women. Where women-specific data exist (menstrual cycle effects on insulin sensitivity, pregnancy PK data), we have cited them. Where they do not exist, we have said so. That transparency is how you can evaluate the confidence level of each recommendation.